Nephrotoxicity in patients with or without cystic fibrosis treated with Polymyxin B compared to colistin

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 4, 2017, Pages

  Crass, Ryan L ^a   Rutter, W Cliff ^a,b   Burgess, Donna R ^a,b   Martin, Craig A ^a,b   Burgess, David S ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Clinical therapeutics; Multidrug resistance; Pharmacokinetics; Pharmacology; Toxicity

Indexed keywords

BILIRUBIN; COLISTIN; CREATININE; POLYMYXIN B; ANTIINFECTIVE AGENT; LOOP DIURETIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; ACUTE KIDNEY INJURY; AGED; BACTERIAL INFECTIONS; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; HOSPITALIZATION; INTENSIVE CARE UNIT; KIDNEY; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL;

ACUTE KIDNEY INJURY; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COLISTIN; CREATININE; CYSTIC FIBROSIS; DIABETES MELLITUS; FEMALE; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; KIDNEY; MALE; MIDDLE AGED; POLYMYXIN B; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 85017006266     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02329-16     Document Type: Article

References (23)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48: 1-12. https://doi.org/10.1086/595011.
2. Boucher HW, Talbot GH, Benjamin DK, Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D; Infectious Diseases Society of America. 2013. 10 - '20 Progress-development of new drugs active against gram-negative bacilli: An update from the Infectious Diseases Society of America. Clin Infect Dis 56: 1685-1694. https://doi.org/10.1093/cid/cit152.
3. Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A, III, Forrest A, Bulitta JB, Tsuji BT. 2010. Resurgence of colistin: A review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30: 1279-1291. https://doi.org/10.1592/phco.30.12.1279.
4. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55: 3284-3294. https://doi.org/10.1128/AAC.01733-10.
5. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE. 2012. Application of a loading dose of colistin methanesulfonate in critically ill patients: Population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56: 4241-4249. https://doi.org/10.1128/AAC.06426-11.
6. Karaiskos I, Friberg LE, Pontikis K, Ioannidis K, Tsagkari V, Galani L, Kostakou E, Baziaka F, Paskalis C, Koutsoukou A, Giamarellou H. 2015. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients. Antimicrob Agents Chemother 59: 7240-7248. https://doi.org/10.1128/AAC.00554-15.
7. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53: 3430-3436. https://doi.org/10.1128/AAC.01361-08.
8. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: Implications for selection of dosage regimens. Clin Infect Dis 57: 524-531. https://doi.org/10.1093/cid/cit334.
9. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. 2009. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 65: 431-434. https://doi.org/10.1016/j.diagmicrobio.2009.07.018.
10. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. 2013. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 57: 1300-1303. https://doi.org/10.1093/cid/cit453.
11. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. 2014. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43: 349-352. https://doi.org/10.1016/j.ijantimicag.2013.12.002.
12. Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, Musick WL, Cottreau JM, Hu M, Tam VH. 2014. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 58: 2740-2746. https://doi.org/10.1128/AAC.02476-13.
13. Reed MD, Stern RC, O'Riordan MA, Blumer JL. 2001. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 41: 645-654. https://doi.org/10.1177/00912700122010537.
14. Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, Etherington C, Turnidge J. 2003. Steady-state pharmacokinetics of intravenous colis- tin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 52: 987-992. https://doi.org/10.1093/jac/dkg468.
15. Rigatto MH, Oliveira MS, Perdigao-Neto LV, Levin AS, Carrilho CM, Tanita MT, Tuon FF, Cardoso DE, Lopes NT, Falci DR, Zavascki AP. 8 February 2016. Renal failure in patients treated with colistin versus polymyxin B: A multicenter prospective cohort study. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.02634-15.
16. Nation RL, Garonzik SM, Li J, Thamlikitkul V, Giamarellos-Bourboulis EJ, Paterson DL, Turnidge JD, Forrest A, Silveira FP. 2016. Updated US and European dose recommendations for intravenous colistin: How do they perform? Clin Infect Dis 62: 552-558. https://doi.org/10.1093/cid/civ964.
17. Sirijatuphat R, Limmahakhun S, Sirivatanauksorn V, Nation RL, Li J, Thamlikitkul V. 2015. Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity. Antimicrob Agents Chemother 59: 3224-3232. https://doi.org/10.1128/AAC.00280-15.
18. Dalfino L, Puntillo F, Ondok MJ, Mosca A, Monno R, Coppolecchia S, Spada ML, Bruno F, Brienza N. 2015. Colistin-associated acute kidney injury in severely ill patients: A step toward a better renal care? A prospective cohort study. Clin Infect Dis 61: 1771-1777.
19. Yousef JM, Chen G, Hill PA, Nation RL, Li J. 2012. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 67: 452-459. https://doi.org/10.1093/jac/dkr483.
20. Fiaccadori E, Antonucci E, Morabito S, d'Avolio A, Maggiore U, Regolisti G. 2016. Colistin use in patients with reduced kidney function. Am J Kidney Dis 68: 296-306. https://doi.org/10.1053/j.ajkd.2016.03.421.
21. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N. 2012. High-dose, extended-interval colistin administration in critically ill patients: Is this the right dosing strategy? A preliminary study. Clin Infect Dis 54: 1720-1726. https://doi.org/10.1093/cid/cis286.
22. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative workgroup. 2004. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8: R204-R212. https://doi.org/10.1186/cc2872.
23. Wilhelm SM, Kale-Pradhan PB. 2011. Estimating creatinine clearance: A meta-analysis. Pharmacotherapy 31: 658-664. https://doi.org/10.1592/phco.31.7.658.